SLAMF6 and melanoma: In accordance with this scenario, our studies recently demonstrated that induction and activation of tumor-residing cDC1s could promote generation of tumor-specific T cells, convert poorly T cell-infiltrated tumors into infiltrated TMEs, facilitate an influx of Slamf6+ Tcf1+ T cells into tumors, induce not only the regression of primary but also untreated distant lesions, and overcome resistance to ICIs using mouse models of melanoma and breast cancer16,32–34.